



Immunotherapy in Daily Clinical Practice: Clinical Application and Emerging Opportunities

Friday, 19 October 2018
18.00 – 20.00

ICM – Room 13
Messe Munich
Munich, Germany



Chair

Giuseppe Curigliano, MD, PhD
European Institute of Oncology
University of Milan
Milan, Italy

Faculty

Mario Colombo, PhD
Fondazione IRCCS - Istituto Nazionale dei Tumori
Milan, Italy

Jean-Pascal Machiels, MD, PhD
Cliniques universitaires Saint-Luc
Université catholique de Louvain
Brussels, Belgium

David Planchard, MD, PhD
Gustave Roussy
Villejuif, France

David I. Quinn, MBBS, PhD, FRACP, FACP
University of Southern California
Norris Cancer Hospital
Los Angeles, California, United States

Continuing Medical Education
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

prIME Oncology designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



Agenda

- 18.00 Welcome and introduction
Giuseppe Curigliano, MD, PhD
- 18.05 Patient selection for immunotherapy: Making sense of current and emerging biomarkers
Mario Colombo, PhD
- Coping With the Whirlwind of Change in Lung Cancer Treatment: A Multidisciplinary Team Discussion**
- 18.17 Clinical scenario 1: First-line therapy for metastatic lung cancer
David Planchard, MD, PhD
- 18.29 Clinical scenario 2: Locally advanced lung cancer
David Planchard, MD, PhD
- 18.41 Q & A
- The Emerging Role for Immunotherapy in Head & Neck (H&N) Cancer: A Multidisciplinary Team Discussion**
- 18.45 Clinical scenario 1: Platinum-resistant advanced H&N cancer
Jean-Pascal Machiels, MD, PhD
- 18.57 Q & A
- The Expanding Role of Immunotherapy for Urologic Malignancies: A Multidisciplinary Team Discussion**
- 19.00 Clinical scenario 1: First-line therapy for metastatic bladder cancer
David I. Quinn, MBBS, PhD, FRACP, FACP
- 19.12 Clinical scenario 2: Second-line therapy for metastatic bladder cancer
David I. Quinn, MBBS, PhD, FRACP, FACP
- 19.24 Clinical scenario 3: A patient with BRCA-positive, endocrine-resistant metastatic prostate cancer
David I. Quinn, MBBS, PhD, FRACP, FACP
- 19.36 Q & A
- 19.39 Extending immunotherapy beyond established indications
Giuseppe Curigliano, MD, PhD
- 19.51 Q & A
- 19.53 Reprise of questions from introduction
Giuseppe Curigliano, MD, PhD
- 19.58 Conclusions and prIME Points™
Giuseppe Curigliano, MD, PhD
- 20.00 Adjourn

Better Decisions Start With My prIME

Access hundreds of live events and online activities that help advance your practice and improve clinical outcomes. prIMEoncology.org

This educational activity is supported by a grant from AstraZeneca Pharmaceuticals